Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|June 7, 2011
[Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study]María Costi, Helen Smith, Jesús Reviriego, et al.
Journal of Medical Economics|May 11, 2013
The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in SpainTiago Fonseca, John Clegg, Giuseppe Caputo, et al.
Journal of Medical Economics|December 24, 2016
The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2Tatiana Dilla, Dimitra Alexiou, Ismini Chatzitheofilou, et al.
BMJ Open|August 15, 2020
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in SpainBernd Schweikert, Chiara Malmberg, Mercedes Núñez, et al.
Applied Health Economics and Health Policy|September 28, 2012
Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: the ECOBIM studyTatiana Dilla, Amparo Valladares, Claudia Nicolay, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|March 27, 2013
Direct healthcare costs and clinical outcomes after insulin initiation in patients with type 2 diabetes mellitus in Spain: 24-month follow-up data from the INSTIGATE studyTatiana Dilla, Claudia Nicolay, María Alvarez, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 27, 2019
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in SpainMax Schlueter, Elaine Finn, Silvia Díaz, et al.
Cost Effectiveness and Resource Allocation : C/E|September 3, 2020
Some reflections on the use of inappropriate comparators in CEAJosé Antonio Sacristán, José-María Abellán-Perpiñán, Tatiana Dilla, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 31, 2013
Adherence to therapies in patients with type 2 diabetesLuis-Emilio García-Pérez, María Alvarez, Tatiana Dilla, et al.
Patient Preference and Adherence|November 19, 2009
Physician and patient management of type 2 diabetes and factors related to glycemic control in SpainNicole Rae Yurgin, Kristina Secnik Boye, Tatiana Dilla, et al.
Pageof 4